Tigecycline: a critical safety review

@article{Kaewpoowat2015TigecyclineAC,
  title={Tigecycline: a critical safety review},
  author={Quanhathai Kaewpoowat and Luis Ostrosky-Zeichner},
  journal={Expert Opinion on Drug Safety},
  year={2015},
  volume={14},
  pages={335 - 342}
}
Introduction: The emergence of multidrug-resistant (MDR) infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline, a broad spectrum antibiotic covering against many MDR organisms, has been widely used. However, recent meta-analysis studies have raised a concern for its efficacy and safety. Reviewing tigecycline safety data would enhance the appropriate use of this medication. Areas covered: This article reviews the safety profile of… Expand
Safety evaluation of current therapies for high risk severely-ill patients with carbapenem-resistant infections.
TLDR
The availability of new drugs showing a potent in vitro activity against CR-GNB represents a unique opportunity to face the threat of resistance, while potentially reducing toxicity. Expand
Re-defining tigecycline therapy.
TLDR
Patients who may be treated with monotherapy, according to the official indications and dosages, from those treated with combination treatment, mostly with high dosages in the setting of nosocomial IAIs, possibly caused by MDR bacteria or as a carbapenem-sparing strategy are distinguished. Expand
Safety considerations of current drug treatment strategies for nosocomial pneumonia
TLDR
The safety profiles of the most common antimicrobials for treating nosocomial pneumonia are analyzed, and linezolid seems to be the superior option for treating methicillin-resistant Staphylococcus aureus. Expand
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
  • S. Yaghoubi, A. Zekiy, +5 authors Farajolah Maleki
  • Medicine
  • European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • 2021
TLDR
Tigecycline showed in vitro susceptibility to Coxiella spp, Rickettsia spp. Expand
Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
TLDR
High dose tigecycline treatment is effective and safe for severe infections owing to its lower all-cause mortality, higher clinical cure, microbiological eradication and comparable adverse events. Expand
Safety considerations with new antibacterial approaches for chronic bacterial prostatitis.
TLDR
Most antibacterial agents considered in this review have been administered off-label in the interest of patients, and their use requires particular caution, and readers should be warned of the limited published evidence supporting therapy of CBP with these agents. Expand
Delirium induced by tigecycline treatment for Acinetobacter baumannii infection
TLDR
This work presents what it believes to be the first case of tigecycline-induced delirium, a 77-year-old male patient with end-stage renal disease who was hospitalized due to acute exacerbation of chronic obstructive pulmonary disease, and advises clinicians to be aware of this potential adverse effect of tIGecYcline. Expand
An update on emerging therapies for urinary tract infections
TLDR
This review summarized data on already approved antibiotics, and selected emerging therapies that are currently in phase II and III trials with emphasis on complicated urinary tract infections (cUTIs), and selected dugs in initial and later stages of development. Expand
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children
TLDR
A comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children, which includes epidemiology, risk factors, outcomes, and antimicrobial therapy management, with particular attention being given to new antibiotics. Expand
Carbapenem-Resistant Enterobacteriaceae Infections in Children
TLDR
This article provides a comprehensive review of what is known to date about CRE, including clinical and molecular epidemiology, microbiologic diagnosis, antibiotic treatment options, and outcomes, and focuses on the available data on CRE in the pediatric population. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Tigecycline: an update.
TLDR
An updated overview of tigecycline clinical studies, current microbial resistance patterns, pharmacokinetic/pharmacodynamic investigations, and safety analyses is offered. Expand
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
TLDR
Tigecycline is not better than standard antimicrobial agents for the treatment of serious infections, and assessment with unpublished studies is needed to make appropriate decisions about new agents. Expand
Effectiveness and safety of tigecycline: focus on use for approved indications.
TLDR
Tigecycline was not associated with higher mortality than comparator antibiotics in patients with infections for which there is approval for its use and was as effective as comparators for the treatment of patients with infection that are approved indications for the use of the drug. Expand
Efficacy and safety of tigecycline: a systematic review and meta-analysis.
TLDR
Clinicians should avoid tigecycline monotherapy in the treatment of severe infections and reserve it as a last-resort drug. Expand
Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease
TLDR
Evidence is provided that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE, and prudence with the clinical use of tigECyclines monotherapy in infections is required. Expand
Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
TLDR
A tigecycline dosage of ∼1.2 mg/kg q12h may represent the most appropriate dosage for subsequent evaluation in Phase III clinical trials in children aged 8 to 11 years with selected serious bacterial infections. Expand
Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
TLDR
Pharmacokinetic/pharmacodynamic properties of tigecycline suggest that high- dose regimens may be more effective than low-dose regimens, and candidates for administration of high-dose tigECYcline should be also defined. Expand
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
TLDR
It is demonstrated that tigecycline was efficacious and well tolerated in the treatment of patients with complicated intra-abdominal infections and microbiological modified intent-to-treat populations. Expand
Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.
TLDR
Data from animal experiments and case reports displayed consistent beneficial activity of tigecycline in combination with other antibacterials against multiresistant organisms, including vancomycin against penicillin-resistant S. pneumoniae in experimental meningitis, gentamicin against Pseudomonas aeruginosa in experimental pneumonia, daptomycin against Enterococcus faecium endocarditis, and colistin against K. pneumoniaE. Expand
Tigecycline Use in Cancer Patients With Serious Infections: A Report on 110 Cases From a Single Institution
TLDR
The combination of tigecycline and an antipseudomonal drug may be appropriate for treating refractory infections and multidrug-resistant organisms in cancer patients, including hematopoietic stem cell transplant recipients. Expand
...
1
2
3
4
5
...